Advertisement

A VOYAGER Meta-Analysis of the Impact of Statin Therapy on Low-Density Lipoprotein Cholesterol and Triglyceride Levels in Patients With Hypertriglyceridemia

Published:February 16, 2016DOI:https://doi.org/10.1016/j.amjcard.2016.02.011
      Elevated triglyceride (TG) levels are associated with increased cardiovascular disease risk. In patients with mild-to-moderate hypertriglyceridemia, defined by the European Atherosclerosis Society Consensus Panel as a TG level of 177 to 885 mg/dl (2.0 to 10.0 mmol/L), low-density lipoprotein cholesterol (LDL-C) reduction remains the primary treatment goal. Using data from the indiVidual patient meta-analysis Of statin therapY in At risk Groups: Effects of Rosuvastatin, atorvastatin and simvastatin (VOYAGER) meta-analysis, we analyzed LDL-C and TG reductions in patients with baseline TG ≥177 mg/dl (≥2.0 mmol/L). Least squares mean percentage change from baseline in LDL-C and TG was compared using 15,800 patient exposures to rosuvastatin 5 to 40 mg, atorvastatin 10 to 80 mg, and simvastatin 10 to 80 mg in patients with baseline TG ≥177 mg/dl (≥2.0 mmol/L). Comparisons were made using mixed-effects models with data only from studies directly comparing treatments by randomized design. Mean LDL-C reductions ranged from −26.9% to −55.5%. Rosuvastatin 10 to 40 mg resulted in significantly greater LDL-C reductions than equal or double doses of atorvastatin and simvastatin (p <0.05). Mean TG reductions ranged from −15.1% to −31.3%. Rosuvastatin 10 mg resulted in significantly greater TG reductions than atorvastatin 10 mg (p <0.05). Rosuvastatin 20 and 40 mg resulted in TG reductions similar to those with equal doses of atorvastatin. Rosuvastatin 10 to 40 mg resulted in significantly greater TG reductions than equal or double doses of simvastatin (p <0.05). In conclusion, in patients with hypertriglyceridemia, LDL-C reduction was substantial and dependent on the choice and dose of statin. TG reduction was numerically less than for LDL-C, and additional TG-lowering therapy may be considered to further reduce residual cardiovascular risk.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Sarwar N.
        • Danesh J.
        • Eiriksdottir G.
        • Sigurdsson G.
        • Wareham N.
        • Bingham S.
        • Boekholdt S.M.
        • Khaw K.T.
        • Gudnason V.
        Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies.
        Circulation. 2007; 115: 450-458
        • Sarwar N.
        • Sandhu M.S.
        • Ricketts S.L.
        • Butterworth A.S.
        • Di Angelantonio E.
        • Boekholdt S.M.
        • Ouwehand W.
        • Watkins H.
        • Samani N.J.
        • Saleheen D.
        • Lawlor D.
        • Reilly M.P.
        • Hingorani A.D.
        • Talmud P.J.
        • Danesh J.
        Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.
        Lancet. 2010; 375: 1634-1639
        • Varbo A.
        • Benn M.
        • Tybjaerg-Hansen A.
        • Jorgensen A.B.
        • Frikke-Schmidt R.
        • Nordestgaard B.G.
        Remnant cholesterol as a causal risk factor for ischemic heart disease.
        J Am Coll Cardiol. 2013; 61: 427-436
        • Nordestgaard B.G.
        • Varbo A.
        Triglycerides and cardiovascular disease.
        Lancet. 2014; 384: 626-635
        • Miller M.
        • Cannon C.P.
        • Murphy S.A.
        • Qin J.
        • Ray K.K.
        • Braunwald E.
        Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial.
        J Am Coll Cardiol. 2008; 51: 724-730
        • Hegele R.A.
        • Ginsberg H.N.
        • Chapman M.J.
        • Nordestgaard B.G.
        • Kuivenhoven J.A.
        • Averna M.
        • Boren J.
        • Bruckert E.
        • Catapano A.L.
        • Descamps O.S.
        • Hovingh G.K.
        • Humphries S.E.
        • Kovanen P.T.
        • Masana L.
        • Pajukanta P.
        • Parhofer K.G.
        • Raal F.J.
        • Ray K.K.
        • Santos R.D.
        • Stalenhoef A.F.
        • Stroes E.
        • Taskinen M.R.
        • Tybjaerg-Hansen A.
        • Watts G.F.
        • Wiklund O.
        The polygenic nature of hypertriglyceridaemia: implications for definition, diagnosis, and management.
        Lancet Diabetes Endocrinol. 2014; 2: 655-666
        • Berglund L.
        • Brunzell J.D.
        • Goldberg A.C.
        • Goldberg I.J.
        • Sacks F.
        • Murad M.H.
        • Stalenhoef A.F.
        Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline.
        J Clin Endocrinol Metab. 2012; 97: 2969-2989
        • Catapano A.L.
        • Reiner Z.
        • De Backer G.
        • Graham I.
        • Taskinen M.R.
        • Wiklund O.
        • Agewall S.
        • Alegria E.
        • Chapman M.
        • Durrington P.
        • Erdine S.
        • Halcox J.
        • Hobbs R.
        • Kjekshus J.
        • Filardi P.P.
        • Riccardi G.
        • Storey R.F.
        • Wood D.
        ESC/EAS guidelines for the management of dyslipidaemias. The task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).
        Atherosclerosis. 2011; 217: 3-46
        • Chapman M.J.
        • Ginsberg H.N.
        • Amarenco P.
        • Andreotti F.
        • Boren J.
        • Catapano A.L.
        • Descamps O.S.
        • Fisher E.
        • Kovanen P.T.
        • Kuivenhoven J.A.
        • Lesnik P.
        • Masana L.
        • Nordestgaard B.G.
        • Ray K.K.
        • Reiner Z.
        • Taskinen M.R.
        • Tokgozoglu L.
        • Tybjaerg-Hansen A.
        • Watts G.F.
        Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.
        Eur Heart J. 2011; 32: 1345-1361
        • Nicholls S.J.
        • Brandrup-Wognsen G.
        • Palmer M.
        • Barter P.J.
        Meta-analysis of comparative efficacy of increasing dose of atorvastatin versus rosuvastatin versus simvastatin on lowering levels of atherogenic lipids (from VOYAGER).
        Am J Cardiol. 2010; 105: 69-76
        • Cannon C.P.
        • Braunwald E.
        • McCabe C.H.
        • Rader D.J.
        • Rouleau J.L.
        • Belder R.
        • Joyal S.V.
        • Hill K.A.
        • Pfeffer M.A.
        • Skene A.M.
        Intensive versus moderate lipid lowering with statins after acute coronary syndromes.
        N Engl J Med. 2004; 350: 1495-1504
        • LaRosa J.C.
        • Grundy S.M.
        • Waters D.D.
        • Shear C.
        • Barter P.
        • Fruchart J.C.
        • Gotto A.M.
        • Greten H.
        • Kastelein J.J.
        • Shepherd J.
        • Wenger N.K.
        Intensive lipid lowering with atorvastatin in patients with stable coronary disease.
        N Engl J Med. 2005; 352: 1425-1435
        • Fruchart J.C.
        • Sacks F.M.
        • Hermans M.P.
        • Assmann G.
        • Brown W.V.
        • Ceska R.
        • Chapman M.J.
        • Dodson P.M.
        • Fioretto P.
        • Ginsberg H.N.
        • Kadowaki T.
        • Lablanche J.M.
        • Marx N.
        • Plutzky J.
        • Reiner Z.
        • Rosenson R.S.
        • Staels B.
        • Stock J.K.
        • Sy R.
        • Wanner C.
        • Zambon A.
        • Zimmet P.
        The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in dyslipidaemic patient.
        Diab Vasc Dis Res. 2008; 5: 319-335
        • Schwartz G.G.
        • Abt M.
        • Bao W.
        • DeMicco D.
        • Kallend D.
        • Miller M.
        • Mundl H.
        • Olsson A.G.
        Fasting triglycerides predict recurrent ischemic events in patients with acute coronary syndrome treated with statins.
        J Am Coll Cardiol. 2015; 65: 2267-2275
        • Rosenson R.S.
        • Davidson M.H.
        • Hirsh B.J.
        • Kathiresan S.
        • Gaudet D.
        Genetics and causality of triglyceride-rich lipoproteins in atherosclerotic cardiovascular disease.
        J Am Coll Cardiol. 2014; 64: 2525-2540
        • Jones P.H.
        • Davidson M.H.
        • Stein E.A.
        • Bays H.E.
        • McKenney J.M.
        • Miller E.
        • Cain V.A.
        • Blasetto J.W.
        Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial).
        Am J Cardiol. 2003; 92: 152-160
        • Karlson B.W.
        • Nicholls S.J.
        • Lundman P.
        • Palmer M.K.
        • Barter P.J.
        Achievement of 2011 European low-density lipoprotein cholesterol (LDL-C) goals of either <70 mg/dl or ≥ 50% reduction in high-risk patients: results from VOYAGER.
        Atherosclerosis. 2013; 228: 265-269
        • Cheung R.C.
        • Morrell J.M.
        • Kallend D.
        • Watkins C.
        • Schuster H.
        Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
        Int J Cardiol. 2005; 100: 309-316
        • McKenney J.M.
        • Jones P.H.
        • Adamczyk M.A.
        • Cain V.A.
        • Bryzinski B.S.
        • Blasetto J.W.
        Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial.
        Curr Med Res Opin. 2003; 19: 689-698
        • Balk E.M.
        • Lichtenstein A.H.
        • Chung M.
        • Kupelnick B.
        • Chew P.
        • Lau J.
        Effects of omega-3 fatty acids on serum markers of cardiovascular disease risk: a systematic review.
        Atherosclerosis. 2006; 189: 19-30
        • Boden W.E.
        • Probstfield J.L.
        • Anderson T.
        • Chaitman B.R.
        • Desvignes-Nickens P.
        • Koprowicz K.
        • McBride R.
        • Teo K.
        • Weintraub W.
        Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy.
        N Engl J Med. 2011; 365: 2255-2267
        • Ginsberg H.N.
        • Elam M.B.
        • Lovato L.C.
        • Crouse III, J.R.
        • Leiter L.A.
        • Linz P.
        • Friedewald W.T.
        • Buse J.B.
        • Gerstein H.C.
        • Probstfield J.
        • Grimm R.H.
        • Ismail-Beigi F.
        • Bigger J.T.
        • Goff Jr., D.C.
        • Cushman W.C.
        • Simons-Morton D.G.
        • Byington R.P.
        Effects of combination lipid therapy in type 2 diabetes mellitus.
        N Engl J Med. 2010; 362: 1563-1574
        • Lavigne P.M.
        • Karas R.H.
        The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
        J Am Coll Cardiol. 2013; 61: 440-446
        • Delgado-Lista J.
        • Perez-Martinez P.
        • Lopez-Miranda J.
        • Perez-Jimenez F.
        Long chain omega-3 fatty acids and cardiovascular disease: a systematic review.
        Br J Nutr. 2012; 107: S201-S213
        • Rosenson R.S.
        Statins: can the new generation make an impression?.
        Expert Opin Emerg Drugs. 2004; 9: 269-279
        • Baigent C.
        • Blackwell L.
        • Emberson J.
        • Holland L.E.
        • Reith C.
        • Bhala N.
        • Peto R.
        • Barnes E.H.
        • Keech A.
        • Simes J.
        • Collins R.
        Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.
        Lancet. 2010; 376: 1670-1681
        • Liao J.K.
        Effects of statins on 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition beyond low-density lipoprotein cholesterol.
        Am J Cardiol. 2005; 96: 24F-33F